The Renaissance of Spiramycin in Clinical Practice

Author:

Yakovlev S. V.1ORCID,Suvorova М. Р.1ORCID

Affiliation:

1. I. M. Sechenov First Moscow State Medical University; City Clinical Hospital named after S. S. Yudin

Abstract

Spiramycin is a natural 16-membered macrolide antibiotic that has been used in clinical practice for about 70 years. Despite long-term use, spiramycin retains its position in clinical practice; the resistance of the main respiratory and urogenital pathogens is lower to spiramycin than to 14- and 15-membered macrolides. The interest in spiramycin is due to the fact that its physico-chemical and pharmacokinetic properties are similar to the last semi-synthetic macrolides, and it lacks the disadvantages of erythromycin. Special biological properties of spiramycin explain its consistently high clinical efficacy that has lasted for 70 years of clinical use in various infections. It is necessary to emphasize the uniqueness of spiramycin as an antibiotic with not only the direct effect on microbes, but also non-antibiotic properties. This allowed the experts at the time to declare the «paradox» of spiramycin — the presence of a higher real clinical efficacy than expected according to in vitro studies. Such properties of spiramycin include pro-antibiotic and post-antibiotic effects, immunomodulatory effect, as well as high intracellular and extracellular concentrations of the antibiotic. The review discusses antimicrobial, pharmacokinetic, and pharmacodynamic characteristics of spiramycin and its place in the treatment of various infections — respiratory, ENT, urogenital, gynecological, and dental.

Publisher

Publishing House OKI

Subject

Infectious Diseases,Microbiology (medical),General Medicine,Microbiology

Reference29 articles.

1. Smith C.R. The spiramycin paradox. J Antimicrob Chemother. 1988 Jul; 22 Suppl B: 141–144. doi: 10.1093/jac/22.supplement_b.141.

2. Rubinstein E., Keller N. Spiramycin renaissance. J Antimicrob Chemother. 1998 Nov; 42 (5): 572–576. doi: 10.1093/jac/42.5.572.

3. Yakovlev S.V., Suvorova M.P. Prirodnyj makrolidnyj antibiotik spiramitsin: antimikrobnaya aktivnost', farmakokinetika i klinicheskoe primenenie. Klinicheskaya Gerontologiya. 1997; 2: 46–53. (in Russian)

4. Spiramitsin. Monografiya. S.V. Yakovlev. Moscow: RhonePoulenc Rorer, 1997; 72

5. Chabbert Y.A. Early studies on in-vitro and experimental activity of spiramycin: a review. J Antimicrob Chemother. 1988 Jul;22 Suppl B: 1–11. doi: 10.1093/jac/22.supplement_b.1.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3